← Back
MacroNYT BusinessMay 27, 2026· 1 min read

KFF CEO Drew Altman to Retire, Marking Leadership Transition for Health Policy Research Hub

Drew Altman, CEO of KFF, a leading U.S. health policy research organization, will retire at year-end. His departure marks a significant leadership transition for an entity that has been instrumental in informing national healthcare economic and policy debates.

Drew Altman, the long-serving Chief Executive Officer of KFF (formerly the Kaiser Family Foundation), is set to retire at the close of 2024. Altman's departure marks a significant leadership transition for the non-profit organization, which he steered from a relatively obscure entity into a preeminent independent source of health policy research and analysis in the United States. Under Altman's nearly three-decade tenure, KFF gained considerable influence in shaping public discourse and informing policymakers on critical health-related issues, including Medicare, Medicaid, the Affordable Care Act, and broader healthcare access and costs. The organization's research, polling, and journalism have become widely cited by government agencies, academic institutions, and media outlets, providing non-partisan data and insights crucial for policy formulation and public understanding of the complex U.S. healthcare system. Altman's retirement at the end of the year initiates a search for his successor, a process that will be closely watched by stakeholders across the healthcare policy landscape. The incoming CEO will inherit a well-established institution with a strong reputation for objective analysis, but also the challenge of navigating an evolving healthcare environment characterized by persistent cost pressures, demographic shifts, and ongoing debates over reform. The transition's economic implications are largely indirect, primarily affecting the continuity of KFF's research output and its role in informing economic policy decisions related to healthcare spending, insurance markets, and public health initiatives. The organization's continued rigor in analysis remains vital for economists and policymakers seeking to understand and address the immense economic footprint of the healthcare sector.

Analyst's Take

While KFF's leadership change isn't a direct market mover, the timing could influence the tenor and focus of healthcare policy discussions post-election. A new leader might subtly shift KFF's analytical lens, potentially highlighting different cost drivers or policy solutions, which could, in turn, influence legislative priorities or investment sentiment in specific healthcare sub-sectors (e.g., pharmaceuticals vs. managed care) over the longer term.

Related

Source: NYT Business